Enlivex Therapeutics (ENLV)
(Delayed Data from NSDQ)
$1.44 USD
-0.01 (-0.69%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.45 +0.01 (0.69%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Price, Consensus and EPS Surprise
ENLV 1.44 -0.01(-0.69%)
Will ENLV be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ENLV based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ENLV
Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why
New Strong Buy Stocks for November 3rd
ENLV: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for October 27th
New Strong Buy Stocks for October 19th
BioCardia (BCDA) Gains FDA Nod for ARDS Cell Therapy Study
Other News for ENLV
Analysts Conflicted on These Healthcare Names: Bausch Health Companies (BHC) and Enlivex (ENLV)
Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis
Enlivex Therapeutics Launches Knee Osteoarthritis Trial
Enlivex announces dosing of first two patients in trail on Allocetra
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis